Abiopharma

🔍 Durbin Sean (Executive)

Company: LINDE PLC (LIN)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 4,526 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,676.56 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,112 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 10,564.56 | transaction_form_type: 4 | Footnotes: F2
• Acquired 1,595 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,159.56 | transaction_form_type: 4 | Footnotes: F1
• Sold 745 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 11,414.56 | transaction_form_type: 4 | Footnotes: F2
• Acquired 1,595 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 13,009.56 | transaction_form_type: 4 | Footnotes: F3
• Sold 745 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 12,264.56 | transaction_form_type: 4 | Footnotes: F2
• Acquired 4,526 shares of Performance Share Units (ROC) (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,526.00 | transaction_form_type: 4 | Footnotes: F4, F4
• Sold 4,526 shares of Performance Share Units (ROC) (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4
• Acquired 1,595 shares of Performance Share Units (RTSR) (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,595.00 | transaction_form_type: 4 | Footnotes: F5, F5
• Sold 1,595 shares of Performance Share Units (RTSR) (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F5
• Acquired 2,857 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,857.00 | transaction_form_type: 4 | Footnotes: F6, F7, F7
• Sold 1,595 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F6, F8, F8
• Acquired 23,290 shares of Stock Options (right to buy) at $483.62 per share (Derivative)
  Date: 2026-03-09 | Code: A | Expires: 2036-03-09 | equity_swap_involved: 0 | shares_owned_after: 23,290.00 | transaction_form_type: 4 | Footnotes: F11
• Holds 1,551 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 1,551.00 | Footnotes: F9, F9
• Holds 1,470 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 1,470.00 | Footnotes: F6, F10, F10
• Holds 10,889 shares of Stock Options (right to buy) at $468.77 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2035-03-07 | shares_owned_after: 10,889.00 | Footnotes: F12
• Holds 9,610 shares of Stock Options (right to buy) at $465.29 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2034-03-07 | shares_owned_after: 9,610.00 | Footnotes: F13
• Holds 10,540 shares of Stock Options (right to buy) at $354.14 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2033-03-07 | shares_owned_after: 10,540.00 | Footnotes: F14
• Holds 19,070 shares of Stock Options (right to buy) at $253.68 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2031-03-08 | shares_owned_after: 19,070.00 | Footnotes: F15
• Holds 7,045 shares of Stock Options (right to buy) at $173.13 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2030-03-09 | shares_owned_after: 7,045.00 | Footnotes: F16
• Holds 391 shares of Deferred Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 391.20 | Footnotes: F6, F17, F17

Footnotes:

• F1: Ordinary shares acquired pursuant to the payout of a performance share unit ("PSU") grant made on March 7, 2023.
• F2: Ordinary shares withheld from the payout to cover tax withholdings.
• F3: Ordinary shares acquired pursuant to the payout of a restricted stock unit ("RSU") grant made on March 7, 2023.
• F4: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the average annual return on capital ("ROC") of Linde plc from 2023-2025 measured against ROC goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023.
• F5: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the relative total shareholder return ("RTSR") of Linde plc from 2023-2025 measured against TSR goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023.
• F6: Conversion to Linde plc Ordinary Shares is on a one-for-one basis.
• F7: Restricted Stock Units that will vest in full and payout on or about March 9, 2029 in Linde plc Ordinary Shares on a one-for-one basis.
• F8: Restricted Stock Units that vested in full and paid out on March 9, 2026 in Linde plc Ordinary Shares on a one-for-one basis.
• F9: Restricted Stock Units that will vest in full and payout on or about March 7, 2028 in Linde plc Ordinary Shares on a one-for-one basis.
• F10: Restricted Stock Units that will vest in full and payout on or about March 7, 2027 in Linde plc Ordinary Shares on a one-for-one basis.
• F11: This option vests over three years in three consecutive equal annual installments beginning on March 9, 2027.
• F12: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2026.
• F13: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2025.
• F14: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2024.
• F15: This option vests over three years in three consecutive equal annual installments beginning on March 8, 2022.
• F16: This option vests over three years in three consecutive equal annual installments beginning on March 9, 2021.
• F17: Deferred stock units acquired under the Linde Compensation Deferral Plan as amended ("Plan"). The deferred stock units will payout in Linde plc Ordinary Shares on a one-for-one basis in accordance with the Plan.